In a nutshell The study reports the outcomes of cancer treatment on the health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (MM) who were not eligible for a stem cell transplant (SCT). This study showed that treatment with VMP (bortezomib, melphalan, and prednisone) with or without daratumumab (Darzalex) improved...
Read MoreSignificance of health related quality of life to confirm the benefits of D-VMP therapy in patients with newly diagnosed multiple myeloma
